Poseida Therapeutics reports Q3 EPS 21c, consensus 41c

Reports Q3 revenue $71.7M, consensus $16.27M. The company expects that its cash, cash equivalents and short-term investments of $230.9M together with these and other remaining near-term milestones and other payments from Roche will be sufficient to fund operations into early 2026. “Poseida continues to make excellent progress across all of our key initiatives, highlighted by compelling data presentations from our pipeline of innovative, non-viral allogeneic cell therapy and genetic medicine programs, the expansion and advancement of our collaborations with Roche and Astellas, and our science-backed strategy to apply our platform to the large and growing opportunity for CAR-T in autoimmune diseases,” said CEO Kristin Yarema. “As a result, we have generated $130M in non-dilutive, partnership related milestones and payments so far this year, along with $49M earned through R&D expense reimbursements. This has resulted in Poseida being cash flow positive for the first nine months of the year and extended our cash runway, with additional upside potential from continued execution, clinical progress and business development. We look forward to sharing updates on our CAR-T programs at our upcoming Cell Therapy R&D Day and future medical meetings.”